Evaluate COLL stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in COLL? | Glauxie AI

Q: What are the risks of investing in COLL?

Collegium Pharmaceutical, Inc. (COLL) operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector). The company is led by CEO Vikram Karnani. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release,... Employees: 423.

Q: How much debt does COLL have?

Review COLL total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is COLL a good long-term investment?

Evaluate COLL as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in COLL?

🦉

Collegium Pharmaceutical, Inc. (COLL)

Company Overview

Sector / IndustryHealthcare / Drug Manufacturers - Specialty & Generic

CEOVikram Karnani

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and...

Key Executives

Name	Title
Colleen Tupper	Executive Vice President & Chief Financial Officer
David Dieter	Executive Vice President, General Counsel & Corporate Secretary
Dean J. Patras	Chief People Officer
Ian Karp	Head of Investor Relations
Jane Gonnerman	Executive Vice President of Strategy & Corporate Development
Jessica Cotrone	Senior Vice President of Communications & Corporate Affairs

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

COLL Profile Financials

Is COLL stock safe? How much debt does COLL have? Is COLL a good long-term investment?